[Troponins and the indication for treatment with IIb/IIa inhibitors in acute coronary syndromes without ST-segment elevation. Is it time for an "INR" value of troponins?].
At the present time non-ST elevation acute coronary syndromes are the most important cause of hospital admissions. Troponin determination in clinical practice is a key element of diagnosis, risk evaluation and prognosis, and now, defines the population that will benefit from IIb/IIIa inhibitors treatment. Probably a "universal standard value of Troponins" is needed to uniform our therapeutic criteria. The "minor elevations" for troponin-I are considered < 0.4 ng/dL and 0.5 ng/dL for troponin-T. The treatment of non ST elevation acute myocardial infarction with IIb/IIIa inhibitors may reduce the total amount of troponins and myocardial damage.
Juárez Herrera
Ursulo
U
Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D.F. ujuarez@mail.medinet.net.mx
D000208:Acute Disease; D003324:Coronary Artery Disease / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D003328:Coronary Thrombosis / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D013577:Syndrome; D014336:Troponin / Q000097:blood*
D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D014336:Troponin
Las troponinas y la indicación de los inhibidores IIb/IIIa en los síndromes coronarios agudos sin elevación del segmento ST. Es tiempo de un valor "INR" de troponinas?